Skip to main content
. 2018 Aug 7;9:1094. doi: 10.3389/fphys.2018.01094

FIGURE 2.

FIGURE 2

Therapeutic approaches to target SIRT3. SIRT3 activity can be modulated by an increase in NAD+ availability and through direct SIRT3 activation. SIRT3 activity prevents cardiac hypertrophy thereby inhibiting the development of HF. Possible nutritional supplements and compounds that increase SIRT3 activation are shown in blue. C12, 7-hydroxyl-3-(4′-metoxyphenyl) coumarin; CR, caloric restriction; HKL, honokiol; NAAD, nicotinic acid adenine dinucleotide; NAMN, nicotinic acid mononucleotide; NAM, nicotinamide; NAMPT, nicotinamide phosphoribosyltransferase; NMN, nicotinamide mononucleotide; NMNAT, nicotinamide mononucleotide adenylyltransferase; NR, nicotinamide ribose.